Anesthesia with ciprofol in cardiac surgery with cardiopulmonary bypass:A case report
作者机构：Department of AnesthesiologyEast HospitalTongji University School of MedicineShanghai 200120China Laboratory of Tumor Molecular BiologySchool of Basic Medical SciencesShanghai University of Medicine and Health SciencesShanghai 201318China Department of AnesthesiologyShanghai East Hospital of Tongji UniversityShanghai 200120China
出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)
年 卷 期：2023年第11卷第1期
页 面：157-163页
核心收录：
主 题：Ciprofol Coronary artery bypass grafting Left ventricular aneurysmectomy Cardiopulmonary bypass Case report
摘 要：BACKGROUND Ciprofol is a novel agent for intravenous general anesthesia.In February 2022,it was approved by the National Medical Products Administration for general anesthesia induction and maintenance.It has the advantages of fast onset,fast elimination,stable circulation,and few adverse reactions.However,the efficacy and safety of ciprofol in cardiac surgery with cardiopulmonary bypass have not been reported.Here we describe a case where ciprofol was successfully used for anesthesia in cardiac surgery with cardiopulmonary bypass.CASE SUMMARY A 72-year-old man(height 176 cm;weight 70 kg)was diagnosed with coronary atherosclerotic cardiomyopathy requiring coronary artery bypass grafting and left ventricular aneurysmectomy.Ciprofol was administered for induction(0.4 mg/kg)and maintenance(0.6-1.0 mg/kg/h)of general anesthesia.During the entire operation,the bispectral index,hemodynamics,and blood oxygen saturation were maintained at normal levels.The patient recovered well after surgery,with no serious adverse events related to ciprofol.CONCLUSION Ciprofol is safe and effective for anesthesia in cardiac surgery with cardiopulmonary bypass.
维普期刊数据库